Key facts
- This page summarizes Jay Sial's Form 4/A - Amendment filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Mar 2022, 21:00.
Jay Sial - 11 Mar 2022 Form 4/A - Amendment Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)
- Reporting relationship
- Chief Administration Officer
- Issuer ticker
- ERNA
- Reported as of
- 11 Mar 2022
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 17 Mar 2022, 21:00:24 UTC
- Original report date
- 15 Mar 2022
- Prior SEC filing
- 19 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jay Sial
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jay Sial filed Form 4/A - Amendment for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 17 Mar 2022.
Change
- Previous filing in this sequence was filed on 19 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ERNA
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +117,200
- Change %
- Price
- $0.000000
- Shares after
- 117,200
- Date
- 11 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 117,200
- Exercise price
- $1.93
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest and become exercisable in 36 substantially equal monthly installments from the grant date.
SEC remarks
This Form 4/A amends and restates the original Form 4 filed by the reporting person on March 15, 2022 (the "Original Form 4"). The Original Form 4 reported incorrect vesting terms.